Hospital
Meadowview Regional Medical Center LLC
Meadowview Regional Medical Center LLC was paid $22.57M by Medicaid between Jan 2018 and Dec 2024, across 232 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoMEADOWVIEW REGIONAL MEDICAL CENTER LLC
MAYSVILLE, KY 41056
MAYSVILLE, KY 41056
33aNPI1881785863assigned 09/27/2006
33bProvider typeRural Acute Care Hospital
28Total paid$22.57M
24GClaims540,284
24DCodes billed232
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#7 of 10
Median peer was paid$23.35M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,597 | $4.31M | |
| 2019 | 66,076 | $3.21M | |
| 2020 | 64,383 | $2.14M | |
| 2021 | 79,280 | $2.58M | |
| 2022 | 77,970 | $2.82M | |
| 2023 | 98,214 | $3.89M | |
| 2024incomplete | 79,764 | $3.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 25,833 | 21,402 | $4.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 8,981 | 6,361 | $2.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 21,225 | 18,399 | $2.30M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 1,981 | 1,590 | $948K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.9% | 2,528 | 2,081 | $878K |
| G0378 | Hospital observation service, per hour | 3.5% | 1,950 | 1,424 | $780K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 1,753 | 1,417 | $760K |
| 93458 | 2.8% | 405 | 206 | $638K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 3,257 | 2,425 | $565K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 11,161 | 7,614 | $418K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 7,462 | 2,354 | $369K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 10,466 | 8,359 | $347K |
220 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 7,659 | $329K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.2% | 903 | $280K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 6,587 | $271K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 3,913 | $266K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 2,779 | $250K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 13,646 | $247K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 3,333 | $246K |
| 80053 | Comprehensive metabolic panel | <1% | 26,599 | $218K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,310 | $216K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,169 | $205K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,271 | $203K |
| 74022 | <1% | 1,610 | $184K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,204 | $172K |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,358 | $170K |
| 59025 | Fetal non-stress test | <1% | 2,320 | $169K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,331 | $165K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,050 | $162K |
| 93017 | <1% | 632 | $151K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,745 | $150K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,168 | $146K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,026 | $141K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,210 | $131K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,057 | $122K |
| 73630 | <1% | 1,443 | $121K | |
| 93454 | <1% | 92 | $119K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,259 | $113K |
| 73130 | <1% | 1,292 | $109K | |
| 73610 | <1% | 1,278 | $104K | |
| 73564 | <1% | 1,178 | $87K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,220 | $72K |
| 84484 | <1% | 7,515 | $69K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,338 | $68K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,320 | $67K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,108 | $67K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,843 | $64K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,878 | $63K |
| 71250 | <1% | 398 | $62K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 134 | $59K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13,461 | $55K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,704 | $51K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,783 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,648 | $48K |
| 81025 | <1% | 5,992 | $45K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,192 | $45K |
| 76642 | <1% | 459 | $45K | |
| 73030 | <1% | 632 | $45K | |
| 87081 | <1% | 7,394 | $42K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,904 | $42K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,580 | $41K |
| C1769 | Guide wire | <1% | 710 | $41K |
| 80061 | Lipid panel | <1% | 3,237 | $40K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 166 | $40K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 460 | $40K |
| 87653 | <1% | 1,392 | $40K | |
| 81001 | <1% | 15,749 | $40K | |
| C1776 | Joint device (implantable) | <1% | 14 | $39K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 821 | $39K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 163 | $38K |
| 72100 | <1% | 465 | $34K | |
| 88304 | <1% | 543 | $34K | |
| 73110 | <1% | 392 | $33K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 104 | $32K |
| 97161 | <1% | 950 | $32K | |
| 84702 | <1% | 2,408 | $31K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 544 | $29K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 123 | $27K |
| 83690 | <1% | 5,102 | $26K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,105 | $24K |
| 87040 | <1% | 2,590 | $24K | |
| 83880 | <1% | 1,162 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,381 | $21K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 551 | $21K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 47 | $20K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,346 | $20K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 218 | $19K |
| 82962 | <1% | 6,147 | $19K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,090 | $19K |
| 83605 | <1% | 2,631 | $19K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 194 | $19K |
| 84439 | <1% | 2,482 | $18K | |
| 76770 | <1% | 123 | $18K | |
| 87420 | <1% | 1,702 | $18K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 92 | $18K |
| 87077 | <1% | 3,769 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 58 | $18K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,780 | $17K |
| 87186 | <1% | 2,598 | $17K | |
| 82805 | <1% | 436 | $17K | |
| 90715 | <1% | 927 | $16K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,209 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 541 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 544 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,212 | $15K |
| 70486 | <1% | 45 | $15K | |
| 85610 | <1% | 3,860 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,439 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,146 | $14K |
| 82565 | <1% | 1,233 | $14K | |
| 87070 | <1% | 2,129 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 778 | $13K |
| 71271 | <1% | 90 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,595 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,474 | $12K |
| 82150 | <1% | 2,275 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 775 | $11K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 307 | $11K |
| 93880 | <1% | 116 | $11K | |
| 85379 | <1% | 1,454 | $11K | |
| 85730 | <1% | 2,825 | $11K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 279 | $10K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,566 | $10K |
| 83735 | <1% | 2,018 | $10K | |
| 86140 | <1% | 2,361 | $9K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 33 | $9K |
| 82728 | <1% | 879 | $9K | |
| 29125 | <1% | 151 | $9K | |
| 85027 | <1% | 920 | $8K | |
| 87210 | <1% | 1,611 | $8K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 57 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 435 | $7K |
| 0240U | <1% | 330 | $7K | |
| 73080 | <1% | 104 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 93 | $7K |
| 73502 | <1% | 215 | $6K | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 314 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 787 | $6K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 89 | $5K |
| 83550 | <1% | 790 | $5K | |
| 87205 | <1% | 1,527 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,016 | $5K |
| 85652 | <1% | 1,945 | $4K | |
| C1758 | Catheter, ureteral | <1% | 1,011 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 110 | $4K |
| 72141 | <1% | 15 | $4K | |
| 83540 | <1% | 834 | $4K | |
| 94060 | <1% | 46 | $4K | |
| 93971 | <1% | 16 | $4K | |
| 36600 | <1% | 529 | $4K | |
| 82607 | <1% | 369 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,107 | $4K |
| 84703 | <1% | 668 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 438 | $3K |
| 88342 | <1% | 79 | $3K | |
| 86900 | <1% | 810 | $3K | |
| 74018 | <1% | 40 | $3K | |
| 82542 | <1% | 227 | $3K | |
| 96367 | <1% | 311 | $3K | |
| 82746 | <1% | 240 | $2K | |
| 29515 | <1% | 42 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 124 | $2K |
| 12001 | <1% | 28 | $2K | |
| 80076 | <1% | 265 | $2K | |
| 84132 | <1% | 538 | $2K | |
| 72110 | <1% | 15 | $2K | |
| 76536 | <1% | 18 | $2K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 47 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 784 | $2K |
| 82248 | <1% | 468 | $2K | |
| 86901 | <1% | 612 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 97 | $2K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 35 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 275 | $1K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 449 | $1K |
| 80074 | <1% | 25 | $1K | |
| 82570 | <1% | 421 | $1K | |
| 83525 | <1% | 95 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 60 | $1K |
| 84112 | <1% | 16 | $1K | |
| 88307 | <1% | 16 | $1K | |
| 10060 | <1% | 14 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $1K |
| 77080 | <1% | 31 | $990.50 | |
| J1815 | Injection, insulin, per 5 units | <1% | 136 | $987.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 829 | $927.70 |
| 86850 | <1% | 147 | $853.30 | |
| 74019 | <1% | 14 | $829.36 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 28 | $765.40 |
| 82550 | <1% | 119 | $712.66 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 79 | $697.74 |
| 82553 | <1% | 82 | $663.04 | |
| 99499 | <1% | 16 | $620.65 | |
| 84550 | <1% | 221 | $620.22 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16 | $611.38 |
| 83516 | <1% | 42 | $584.76 | |
| 93923 | <1% | 18 | $562.11 | |
| 86665 | <1% | 12 | $554.41 | |
| Q9964 | High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | <1% | 40 | $546.39 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 24 | $539.16 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 28 | $518.56 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 192 | $500.79 |
| 88300 | <1% | 13 | $456.02 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 17 | $449.58 |
| 80051 | <1% | 49 | $429.77 | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | <1% | 12 | $424.29 |
| 87493 | <1% | 12 | $402.73 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 37 | $382.70 |
| 84156 | <1% | 172 | $354.96 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 366 | $332.50 |
| 97165 | <1% | 13 | $326.98 | |
| 84520 | <1% | 98 | $320.16 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 145 | $278.97 |
| 82272 | <1% | 77 | $265.31 | |
| 86645 | <1% | 12 | $257.43 | |
| 86664 | <1% | 12 | $233.66 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 48 | $230.39 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 96 | $222.33 |
| 86644 | <1% | 12 | $219.94 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 13 | $208.37 |
| 86663 | <1% | 12 | $200.42 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 227 | $133.40 |
| 82247 | <1% | 20 | $102.35 | |
| 85347 | <1% | 28 | $99.52 | |
| 86431 | <1% | 14 | $73.28 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 30 | $63.13 |
| 85045 | <1% | 12 | $36.63 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 19 | $30.25 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12 | $28.96 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 22 | $20.69 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 15 | $0.72 |
| A9270 | Non-covered item or service | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.